• Our CiPA Instruments

    HESI FDA BAA study: "Assessing variability and reproducibility of manual and automated patch clamp platforms"

  • CiPA hERG Protocol

    This protocol was used for hERG studies on the Patchliner and SyncroPatch 384PE.

  • HTS CiPA hERG Assay

    Effects of Cisapride using the CiPA hERG protocol on the SyncroPatch 384PE

  • Myocyte & Ion Channel Effects

    Arrhythmic Field potentials in iPSC-derived Cardiomyocytes (CardioExcyte 96) and hERG current inhibition (SyncroPatch 384PE)

  • Gigaseal HTS patch clamp

    CiPA-specified cardiac ion channels recorded at high throughput

  • Gigaseal HTS patch clamp

    High throughput recordings of cardiac ion channels at physiological temperature

  • CardioExcyte 96 screening tool

    CardioExcyte 96 with integrated liquid handling for cardiac safety screening

2018 - Assessment of Drug Effects on Cardiomyocyte Function: Comprehensive In Vitro Proarrhythmia Assay (CiPA) Results

Icon CE   CardioExcyte 96 poster, SOT Meeting 2018  logo pdf   (1.8 MB)


The on-going comprehensive in vitro pro-arrhythmia assay (CiPA) initiative aims to improve drug safety testing and help more beneficial chemical entities reach the market. The project consists of three main parts, which include 1) electrophysiological investigation of drug effects on human ventricular ion channels, 2) characterization of the in-silico cardiosafety model predictions, 3) assessment of discrepancies and gaps in fully integrated biological systems (human induced pluripotent stem-cell derived cardiac myocytes (iPSC- CMs) and the human ECG). To assess and validate drug effects on hiPSC-CMs in a combined measurement of cardiac excitation and contraction, a subset of compounds which are part of the Phase II CiPA study were tested. A prospective comparison study using combined extracellular field potential (EFP) and impedance technology was conducted across 4 independent laboratories testing 12 reference compounds in 4 independent commercially available hiPSC-CMs. Our data demonstrates that hERG channel blockers, such as Sotalol and Dofetilide prolonged field potential duration (FPD) at low concentration and induced arrhythmia as measured by field potential (FP) recording and impedance (IMP) recordings at higher concentrations. The cross-cell comparison displayed different minimal effective concentrations regarding FPD prolongation and cessation of beating. On the contrary, Diltiazem, a calcium channel inhibitor, weakened cell contractile activity and shortened FPD. Multichannel inhibitors, such Quinidine increased FPD, weakened the contraction force and induced arrhythmia. Furthermore, validation on low risk proarrhythmia compounds such as Tamoxifen and intermediate risk compounds such as Droperidol will be presented. Comparison of the compound effects across the four different sites showed the consistent trend of the effect. Taken together, commercially available hiPSC-CMs in conjunction with combined measurements of ion channel activity and contractility is a reliable approach for risk assessment of proarrhythmic compounds.

Back to Overview

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.